Terumo Americas Holding (TAH), a US subsidiary of Terumo, has purchased the assests of Onset Medical.
By utilizing its proprietary controlled deployment technology (CDT), Onset has developed the smallest sheath profiles with the largest internal diameters of any available access sheath which are designed to protect against unnecessary access site or arterial trauma for the patient.
Under the agreement, all the Terumo customers will have access to Onset’s complete product lines including the SoloPath Balloon Expandable Transfemoral and Transseptal catheters’ expandable and collapsable sheath technology.
These catheters provide access to complex, large-bore procedures including transcatheter aortic valve implantation (TAVI), thoracic endovascular aortic/aneurysm repair (TVAR) and endovascular aneurysm/aortic repair (EVAR).
The Terumo customers will also have access to Onset’s Pathway Balloon Expandable PCNL Sheath and Pathway Balloon Expandable Ureteral Access Sheath which offers physicians with a one-step option for performing percutaneous nephrolithotomy procedures to remove large renal calculi (kidney stones).
Onset Medical vice president and COO Joseph Bishop said their devices will immediately strengthen Terumo’s core capability and will be featured prominently among other technologies that drive better patient outcomes.